Bayer Doubles OTC Presence In China With Dihon Acquisition
This article was originally published in PharmAsia News
Executive Summary
Bayer AG acquired its second Chinese over-the-counter company to scale up amid the country’s OTC consolidation trend.
You may also be interested in...
Sanofi Expands China Footprint In OTC And Rx Markets With BMP Sunstone Acquisition
Sanofi-Aventis has gained a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys
China Micron Ban Not Cause For Further Health Sector Worry?
China has taken a new counterstrike against the US in the chips sector, but the risk of potential wider impact on the biopharma sector appears to be limited given other tighter regulations already in place.
'Being Innovative Not Enough': Multinationals Want Driver‘s Seat In Changing China
Multinational pharma firms are exploring their next growth trajectories in China, where some including AstraZeneca and Roche are deepening their commitment by becoming further integrated into local innovation ecosystems and pursuing deals, while others such as Pfizer are focusing on tackling reimbursement challenges.